In this study of study of 385 patients ages 5 or older with a history of multisystem inflammatory syndrome in children (MIS-C), no serious adverse events were reported after COVID-19 vaccination. These findings suggest that the safety profile of COVID-19 vaccination administered at least 90 days following MIS-C diagnosis appears to be similar to that in the general population.
Authors: Matthew D. Elias, M.D., of the Children’s Hospital of Philadelphia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.48987)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.48987?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=010323
Journal
JAMA Network Open
